Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Absolute claudication distance (MWD + PWT) (in meters) · intermittent claudication
1 finding from 1 review
Initial claudication distance (PFWD + COT) (in meters) · intermittent claudication
1 finding from 1 review
Quality of life · intermittent claudication
1 finding from 1 review
Progression of disease (to Fontaine stage III or IV, or necessity for intervention (endovascular or surgery)) · intermittent claudication
1 finding from 1 review
Side effects of propionyl‐L‐carnitine regimen · intermittent claudication
1 finding from 1 review
Ankle brachial index · intermittent claudication
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · acute gout
NSAIDs may leads to higher pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) compared with placebo (low certainty).
1 finding from 1 review
RR 2.75 [1.13, 6.72]
Studies not reported
Low
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
NSAIDs showed no clear difference in inflammation: swelling compared with placebo (low certainty).
1 finding from 1 review
RR 1.08 [0.79, 1.49]
Studies not reported
Low
Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout
NSAIDs showed no clear difference in function: ≥ 50% improvement in pain with movement at 24 hours compared with placebo (low certainty).
1 finding from 1 review
RR 4 [0.5, 31.74]
Studies not reported
Low
Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.85]
Studies not reported
Low
Reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks SELENA‐SLEDAI score, a validated marker of SLE disease activity (range 0 to 105; higher score = worse disease activity) · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg leads to higher reduction of at least 4 points in SELENA‐SLEDAI at 52 weeks… compared with placebo (high certainty).
1 finding from 1 review
Change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36 PCS score from baseline ( · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg probably leads to higher change in HRQOL, on SF‐36 PCS score at 52 weeks Improvement in SF‐36… compared with placebo (moderate certainty).
1 finding from 1 review
Reduction of glucocorticoid dose by at least 50% · people with active systemic lupus erythematosus (but not active nephritis or active central nervous system involvement)
Belimumab 10 mg/kg leads to higher reduction of glucocorticoid dose by at least 50% compared with placebo (high certainty).
1 finding from 1 review